16 . 09 .2022
Press release
Galderma debuts the Sensitive Skincare Faculty, a global expert group to improve understanding and management of sensitive skin
06 . 09 .2022
Press release
Galderma showcases its continued commitment to innovation in dermatology with new data to be presented at 2022 EADV congress
25 . 08 .2022
Press release
Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio
30 . 06 .2022
Press release
Galderma and Children’s Skin Disease Foundation Celebrate Decade-Long Partnership
22 . 06 .2022
Press release
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis
10 . 06 .2022
Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)
08 . 06 .2022
Press release
Galderma to present new findings from innovative product portfolio at the 2022 VCS Annual Symposium
02 . 06 .2022
Press release
Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
01 . 06 .2022
News story
Actinic Keratosis prevention campaign encourages everyone to ‘FACE THE FACTS’